Molecular targets in therapy for human soft-tissue and bone sarcomas.
Sarcomas represent a heterogeneous group of tumors with different natural histories and therapeutic approaches. Recent discoveries have identified molecular alterations in the pathogenesis of these tumors that lead to distinct effects on sarcoma cell biology. These tumor cell characteristics include independence from growth factors, evasion of apoptosis, and maintenance of genomic integrity. Inhibition of these molecular alterations represents a therapeutic opportunity to reverse the biologic basis of tumor formation in soft-tissue sarcomas and bone tumors.
Steinert
Dejka M
DM
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 450, Houston, TX 77030, USA.
Blakely
L Johnetta
LJ
Salganick
Jason
J
Trent
Jonathan C
JC
D001859:Bone Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008297:Male; D009857:Oncogenes; D012516:Osteosarcoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012509:Sarcoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome